Login / Signup

Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients.

Laila Aldars-GarcíaRubén Gil-RedondoNieves EmbadeSabino RiestraMontserrat RiveroAna GutiérrezIago Rodríguez-LagoLuis Fernández-SalazarDaniel CeballosJosé Manuel BenítezMariam AguasIria Baston-ReyFernando BermejoMaría José CasanovaRufo LorenteYolanda BerDaniel GinardMaría EsteveRuth de FranciscoMaría José GarcíaRubén FrancésAinhoa Rodríguez PescadorBenito VelayosElena Guerra Del RíoSandra Marín PedrosaAlejandro Minguez SabaterManuel Barreiro-de AcostaAlicia AlgabaCristina Verdejo GilOlga RivasVanesa RoyoMontserrat AceitunoAna GarreMontserrat Baldán-MartínCristina RamírezAncor Sanz-GarcíaJuan J LozanoJulia SidorovaOscar MilletDavid BernardoJavier P GisbertMaria Chaparro
Published in: Inflammatory bowel diseases (2023)
This study highlights the molecular alterations present within the different subgroups of newly diagnosed treatment-naïve IBD patients. The metabolomic profile of these patients may provide further understanding of pathogenic mechanisms of IBD subgroups. Serum metabotype seemed to be especially sensitive to the onset of IBD.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes
  • patient reported
  • single molecule